Go Unlimited with Magzter GOLD
Get unlimited access to 10,000+ magazines, newspapers and Premium stories for just
Try GOLD - Free
"Australia has long been a global leader in research, yet our biotech sector has not lived up to its full potential"
BioSpectrum Asia
|BioSpectrum Asia Sep 2024
Australia's first true biotech incubator, Proto Axiom, has secured $20 million in the first close of its $30 million Series B round to strengthen the nation's biotech sector through greater IP retention. Anthony Liveris, CEO of Proto Axio discusses the incubator's selection criteria, identifying the most promising biotech trends for global health, and outlining the key strengths that make Australian biotech globally competitive. Edited excerpts:
Can you provide insight into the selection process for ventures at Proto Axiom? What key factors determine which ideas or projects receive mentorship and funding?
We focus on supporting proof-of-concept research that is poised to reach key commercial milestones. Our primary criteria include groundbreaking research with a well-defined pathway to clinical development. We seek projects that demonstrate strong potential for real-world impact and align with our vision for advancing innovative healthcare solutions.
Could you highlight some of the main support services that you provide to your startups?
This story is from the BioSpectrum Asia Sep 2024 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
India Health Fund supports D-Nome to bolster molecular TB screening in India
India Health Fund (IHF), a Tata Trusts initiative, is poised to transform tuberculosis (TB) screening at scale by enabling the development of the world's most affordable molecular screening tool for TB.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
BioOra and Octane Biotech sign LoI to expand cell therapy manufacturing using Cocoon Platform
BioOra, a commercialstage cell therapy company advancing CAR-T therapies for cancer patients, & Canadabased Octane Biotech Inc., an Octane Medical Group Company, has announced the signing of a Letter of Intent (LOI) to collaborate on the co-development & deployment of advanced cell therapies using the Cocoon automated cell therapy manufacturing platform.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
NTU and NHG Health partner to advance healthcare education in Singapore
NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
Gene Solutions introduces non-invasive prenatal screening technology triSure in Taiwan
Singapore-based startup Gene Solutions has introduced triSure, a revolutionary non-invasive prenatal screening technology.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
How FemTech Spurt in APAC is Redefining Healthcare
Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.
4 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
China's Colossal Ageing Population and Low Birth Rate Challenge
China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.
2 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"
At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.
7 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area
Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.
1 min
BioSpectrum Asia May 2026
BioSpectrum Asia
"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"
More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.
5 mins
BioSpectrum Asia May 2026
BioSpectrum Asia
Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel
Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.
1 min
BioSpectrum Asia May 2026
Listen
Translate
Change font size